Relief in mild-to-moderate pain is not a confounder in joint space narrowing assessment of full extension knee radiographs in recent osteoarthritis structure-modifying drug trials
Pavelka, K.; Bruyère, Olivier; Rovati, Lucio Cet al.
2003 • In Osteoarthritis and Cartilage, 11 (10), p. 730-737
osteoarthritis; glucosamine sulfate; radiographic measurement; joint space width
Abstract :
[en] Objective: To assess whether improvement in knee pain biased the determination of the structure-modifying effect reported for glucosamine sulfate in two recent 3-year, randomised, placebo-controlled clinical trials, in which conventional standing antero-posterior full extension knee radiographs were used for the measurement of joint space narrowing, and in which pain relief might have improved knee full extension. Design: Patients completing the 3-year treatment course were selected based on a WOMAC pain decrease at least equal to the mean improvement in the glucosamine sulfate arms in either of the original studies, irrespective of treatment with glucosamine sulfate or placebo (drug responders or placebo responders). In a second approach, 3-year completers were selected if their baseline standing knee pain (item #5 of the WOMAC pain scale) was 'severe' or 'extreme' and improved by any degree at the end of the trials. In both cases, changes in minimum joint space width were compared between treatment groups. Results: Global knee pain was rnild-to-moderate in the two study populations and in all patient subsets identified. There were obviously more pain improvers in the glucosamine sulfate subsets (N=76 in the two studies combined) than in the placebo subsets (N=57), but WOMAC pain scores improved to the same extent, which was as large as over 50% relative to baseline. Nevertheless, the placebo subsets in both studies underwent an evident mean (SD) joint space narrowing, which in the pooled analysis of both studies was -0.22 (0.80) mm, and was not observed with glucosamine sulfate: +0.15 (0.60) mm (P=0.003 vs placebo). Similar results were found in the smaller subsets with greater than or equal to severe baseline standing knee pain that improved after 3 years, with a joint space narrowing nevertheless of -0.28 (0.76) mm with placebo (N=26), not observed with glucosamine sulfate: +0.21 (0.68) mm (N=31; P=0.014 vs placebo). Conclusions: Knee pain relief did not bias the report of a structure-modifying effect of glucosamine sulfate in two recent long-term trials using conventional standing antero-posterior radiographs, possibly due to the mild-to-moderate patient characteristics. (C) 2003 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
Disciplines :
Rheumatology Orthopedics, rehabilitation & sports medicine
Author, co-author :
Pavelka, K.
Bruyère, Olivier ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
Rovati, Lucio C
Olejarova, M.
Giacovelli, Giampaolo
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
Language :
English
Title :
Relief in mild-to-moderate pain is not a confounder in joint space narrowing assessment of full extension knee radiographs in recent osteoarthritis structure-modifying drug trials
Dougados M for the Group for the Respect of Ethics and Excellence in Science. Recommendations for the registration of drugs used in the treatment of osteoarthritis. Ann Rheum Dis 1996;55:552-7.
Altman R, Brandt K, Hochberg M, Moskowitz R. Design and conduct of clinical trials of patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society. Osteoarthritis Cartilage 1996;4:217-43.
Committee for Proprietary Medicinal Products. Points to consider on clinical investigation of medicinal products used in the treatment of osteoarthritis. The European Agency for the Evaluation of Medicinal Products, July 1998.
Center for Drug Evaluation and Research. Clinical development programs for drugs, devices and biological products intended for the treatment of osteoarthritis. Food and Drug Administration (US), July 1999.
Buckland-Wright JC, Scott WW Jr, Peterfy C. Radiographic imaging techniques. Osteoarthritis Cartilage 1996;4:238-40.
Buckland-Wright C. Radiographic assessment of osteoarthritis: comparison between existing methodologies. Osteoarthritis Cartilage 1999; 7:430-3.
Buckland-Wright JC, Wolfe F, Ward RJ, Flowers N, Hayne C. Substantial superiority of semiflexed (MTP) views in knee osteoarthritis: a comparative radiographic study, without fluoroscopy, of standing extended, semiflexed (MTP), and schuss views. J Rheumatol 1999;26:2664-74.
Mazzuca SA, Brandt KD, Dieppe PA, Doherty M, Katz BP, Lane KA. Effect of alignment of the medial tibial plateau and X-ray beam on apparent progression of osteoarthritis in the standing antero-posterior knee radiograph. Arthritis Rheum 2001;44:1786-94.
Brandt KD, Mazzuca SA, Conrozier T, Dacre JE, Peterfy CG, Provvedini D, et al. Which is the best radiographic protocol for a clinical trial of a structure modifying drug in patients with knee osteoarthritis? J Rheumatol 2002;29:1308-20.
Neuhauser KB, Anderson JJ, Felson DT. Rate of joint space narrowing in normal knees and knees with osteoarthritis. Arthritis Rheum 1994;37(Suppl):S423.
Lethbridge-Cejku M, Hochberg MC, Scott WW Jr, Plato CC, Tobin JD. Longitudinal change in joint space of the knee: data from the Baltimore Longitudinal Study of Aging. Arthritis Rheum 1995;38(Suppl):S262.
Dieppe PA, Cushnaghan J, Shepstone L. The Bristol 'OA500' study: progression of osteoarthritis (OA) over 3 years and the relationship between clinical and radiographic changes at the knee joint. Osteoarthritis Cartilage 1997;5:87-97.
Dieppe P, Cushnaghan J, Tucker M, Browning S, Shepstone L. The Bristol 'OA500 study': progression and impact of the disease after 8 years. Osteoarthritis Cartilage 2000;8:63-8.
Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, et al. Long-term effects of glucosamine sulfate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001; 357:251-6.
Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC. Glucosamine sulfate use and delay of progression of knee osteoarthritis. Arch Intern Med 2002;162:2113-23.
McAlindon T. Glucosamine for osteoarthritis: dawn of a new era?. Lancet 2001;357:247-8.
Mazzuca SA, Brandt KD, Lane KA, Katz BP. Knee pain reduces joint space width in conventional standing anteroposterior radiographs of osteoarthritic knees. Arthritis Rheum 2002;46:1223-7.
Chard J, Dieppe P. Update: treatment of osteoarthritis. Arthritis Rheum (Arthritis Care Res) 2002;47:686-90.
Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Arthritis Rheum 1986; 29:1039-49.
Lequesne M. Quantitative measurements of joint space width during progression of osteoarthritis: chondrometry. In: Kuetter KE, Goldberg VM, Eds. Osteoarthritic Disorders. Rosemont: American Academy of Orthopedic Surgeons 1995;427-44.
Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833-40.
Ravaud P, Auleley G-R, Chastang C, Rousselin B, Paolozzi L, Amor B, et al. Knee joint space width measurement: an experimental study of the influence of radiographic procedure and joint positioning. Br J Rheumatol 1996;35:761-6.
Bruyere O, Honore A, Rovati LC, Giacovelli G, Henrotin YE, Seidel L, et al. Radiologic features poorly predict clinical outcomes in knee osteoarthritis. Scand J Rheumatol 2002;31:13-6.
Bruyere O, Honore A, Ethgen O, Rovati LC, Giacovelli G, Henrotin YE, et al. Correlation between radiographic severity of knee osteoarthritis and future disease progression. Results from a 3-year prospective, placebo-controlled study evaluating the effect of glucosamine sulfate. Osteoarthritis Cartilage 2003; 11:1-5.